BR112014021081A2 - anticorpos para a metaloproteinase da matriz 9 - Google Patents

anticorpos para a metaloproteinase da matriz 9

Info

Publication number
BR112014021081A2
BR112014021081A2 BR112014021081A BR112014021081A BR112014021081A2 BR 112014021081 A2 BR112014021081 A2 BR 112014021081A2 BR 112014021081 A BR112014021081 A BR 112014021081A BR 112014021081 A BR112014021081 A BR 112014021081A BR 112014021081 A2 BR112014021081 A2 BR 112014021081A2
Authority
BR
Brazil
Prior art keywords
antibodies
matrix metalloproteinase
mmp9
functional fragment
binding proteins
Prior art date
Application number
BR112014021081A
Other languages
English (en)
Inventor
I Adamkewicz Joanne
J Hawkins Michael
Smith Victoria
Thai Zung
Original Assignee
Gilead Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/027160 external-priority patent/WO2013130078A1/en
Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc
Publication of BR112014021081A2 publication Critical patent/BR112014021081A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

antibodies to matrix metalloproteinase 9 abstract of the disclosure the present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), such as where the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof). ________________________ tradução do resumo resumo patente de invenção: "anticorpos para a metaloproteina-se da matriz 9". a presente divulgação proporciona composições e métodos de uso envolvendo proteínas de ligação, p.ex., os anticorpos e os seus fragmentos de ligação aos antígenos, que se ligam à proteína metalo-proteinase da matriz 9 (mmp9) (a mmp9 é também conhecida como gelatinase-b), tal como onde as proteínas de ligação compreendem uma cadeia pesada da imunoglobulina (ig) (ou seu fragmento funcio-nal) e uma cadeia leve da ig (ou seu fragmento funcional).
BR112014021081A 2012-02-29 2013-02-28 anticorpos para a metaloproteinase da matriz 9 BR112014021081A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261605181P 2012-02-29 2012-02-29
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9
US201361755444P 2013-01-22 2013-01-22
PCT/US2013/028456 WO2013130905A1 (en) 2012-02-29 2013-02-28 Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number Publication Date
BR112014021081A2 true BR112014021081A2 (pt) 2017-07-04

Family

ID=49003113

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014021081A BR112014021081A2 (pt) 2012-02-29 2013-02-28 anticorpos para a metaloproteinase da matriz 9

Country Status (23)

Country Link
US (2) US9732156B2 (pt)
EP (2) EP3255063A3 (pt)
JP (3) JP6144286B2 (pt)
KR (1) KR20140130513A (pt)
CN (2) CN107184974A (pt)
AP (1) AP2014007921A0 (pt)
AU (1) AU2013203619B2 (pt)
BR (1) BR112014021081A2 (pt)
CA (1) CA2865501A1 (pt)
CL (1) CL2014002258A1 (pt)
CO (1) CO7061039A2 (pt)
CR (1) CR20140451A (pt)
EA (1) EA201491599A1 (pt)
EC (1) ECSP14020644A (pt)
HK (4) HK1204926A1 (pt)
MD (1) MD20140108A2 (pt)
MX (2) MX2014010447A (pt)
MY (1) MY167236A (pt)
NZ (1) NZ629178A (pt)
PH (1) PH12014501927A1 (pt)
SG (2) SG10201610788VA (pt)
WO (1) WO2013130905A1 (pt)
ZA (1) ZA201406318B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2608809T (pt) 2010-08-27 2019-08-26 Gilead Biologics Inc Anticorpos para a metaloproteinase 9 da matriz
SG194710A1 (en) 2011-05-10 2013-12-30 Nestec Sa Methods of disease activity profiling for personalized therapy management
JP6067756B2 (ja) 2012-02-29 2017-01-25 ギリアード バイオロジックス， インコーポレイテッド マトリックスメタロプロテイナーゼ９に対する抗体
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
KR102332302B1 (ko) 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
CN105722532A (zh) 2013-09-13 2016-06-29 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
MX362923B (es) * 2014-01-30 2019-02-25 Coherus Biosciences Inc Medios de perfusión.
EP3110847A1 (en) * 2014-02-27 2017-01-04 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9 and methods of use thereof
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
TWI790593B (zh) 2014-08-19 2023-01-21 美商默沙東有限責任公司 抗tigit抗體
JP6976241B2 (ja) 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ｔｉｇｉｔ抗体
WO2017106566A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
KR101783907B1 (ko) * 2016-03-15 2017-10-10 다이노나(주) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
EP3440113A1 (en) * 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
TWI676482B (zh) * 2017-03-23 2019-11-11 高雄醫學大學 盤基蛋白結構域受體１的抑制劑及活化劑及其用途
WO2018220588A1 (en) 2017-05-31 2018-12-06 Nestec S.A. Methods for assessing mucosal healing in crohn's disease patients
EP3656861A4 (en) 2017-07-18 2021-04-07 Daiichi Sankyo Company, Limited ACTIVE MMP9-BINDING PEPTIDE
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
IL264768A (en) * 2019-02-10 2020-08-31 Sagi Irit ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
EP3972644A4 (en) * 2019-05-21 2024-01-10 Univ California MMP-9 ANTIBODIES AND METHODS OF USE THEREOF
WO2021202592A2 (en) * 2020-03-30 2021-10-07 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
WO2023154814A2 (en) * 2022-02-09 2023-08-17 Sera Prognostics, Inc. Shbg and ibp4 antibodies and methods using same
CN114292834B (zh) * 2022-03-09 2022-05-31 天津辅元生物医药科技有限公司 一种融合蛋白酶及其制备方法、其在提取i型胶原蛋白中的应用以及该i型胶原蛋白的用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
EP0685557B1 (en) 1993-11-30 1998-08-12 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel metalloprotease and dna coding for the same
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
JP2003508352A (ja) 1999-07-13 2003-03-04 ユニバーシティ・オブ・サザン・カリフォルニア ＭＭＰ−９およびβ１インテグリンに基づくアンタゴニストを用いた血管形成の抑制のための新規な方法および組成物
US7101975B1 (en) 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
AU2002235692A1 (en) 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
SE0102298D0 (sv) 2001-06-27 2001-06-27 Astrazeneca Ab Crystal structure of enzyme and uses thereof
WO2003006006A1 (en) 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
AU2002352089A1 (en) 2001-11-23 2003-06-10 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
ES2614274T3 (es) 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
WO2004076614A2 (de) 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
ES2433440T3 (es) 2003-04-04 2013-12-11 Yeda Research And Development Co. Ltd. Anticuerpos contra MMP2 o MMP9 y composiciones farmacéuticas que contienen los mismos útiles para inhibir la actividad de dichas metaloproteínas
ES2364147T3 (es) * 2004-01-16 2011-08-25 Regeneron Pharmaceuticals, Inc. Polipéptidos de fusión capaces de activar receptores.
WO2006037513A1 (en) 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
EP1904846A4 (en) 2005-06-29 2009-03-18 Rules Based Medicine Inc METHOD AND KITS FOR THE DIAGNOSIS OF ACUTE CORONARY SYNDROME
CN101370832B (zh) * 2005-12-02 2014-07-02 健泰科生物技术公司 结合多肽及其用途
AU2006338198B2 (en) * 2005-12-02 2012-04-26 Genentech, Inc. Binding polypeptides and uses thereof
WO2007144781A2 (en) 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
WO2008088864A2 (en) 2007-01-18 2008-07-24 The Trustess Of Columbia University In The City Of New York Matrix metalloproteinase-9-related methods
EP2155691B1 (en) 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
TW200911835A (en) * 2007-06-08 2009-03-16 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
HUE025283T2 (en) 2007-08-02 2016-03-29 Gilead Biologics Inc LOX and LOX2 inhibitors and their use
US20110052572A1 (en) 2007-08-15 2011-03-03 Yeda Research And Development Co. Ltd Regulators of mmp-9 and uses therof
JP2011506614A (ja) 2007-12-17 2011-03-03 ダイアックス コーポレーション Ｍｍｐ−１４結合タンパク質を含む、骨溶解性障害を処置するための組成物および方法
US8008445B2 (en) 2008-03-03 2011-08-30 Dyax Corp. Metalloproteinase 9 binding proteins
EP2262840A4 (en) 2008-03-03 2012-08-08 Dyax Corp METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS
AU2009308369A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
DE102009030321A1 (de) * 2009-06-24 2011-01-05 Siemens Aktiengesellschaft Verfahren zur Abbildung von Tumorgewebe
AU2011210362B2 (en) 2010-01-27 2015-09-10 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
KR20130008021A (ko) 2010-02-04 2013-01-21 길리아드 바이오로직스, 인크. 리실 산화효소-유사 2 (ｌｏｘｌ2)에 결합하는 항체, 및 그를 위한 사용 방법
US8896483B2 (en) * 2010-07-15 2014-11-25 Evgeny Markin Method of automatic target angle tracking by monopulse radar under conditions of interference distorting location characteristic
PT2608809T (pt) * 2010-08-27 2019-08-26 Gilead Biologics Inc Anticorpos para a metaloproteinase 9 da matriz
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
JP6067756B2 (ja) 2012-02-29 2017-01-25 ギリアード バイオロジックス， インコーポレイテッド マトリックスメタロプロテイナーゼ９に対する抗体
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
HK1244671A1 (zh) 2018-08-17
PH12014501927A1 (en) 2014-11-24
HK1204926A1 (en) 2015-12-11
JP2017178952A (ja) 2017-10-05
US20180002446A1 (en) 2018-01-04
CR20140451A (es) 2014-11-17
JP2018150343A (ja) 2018-09-27
HK1248246A1 (zh) 2018-10-12
WO2013130905A1 (en) 2013-09-06
EP2819697A4 (en) 2016-03-09
MY167236A (en) 2018-08-14
JP2015509959A (ja) 2015-04-02
CN107184974A (zh) 2017-09-22
AU2013203619A1 (en) 2013-09-19
CN104271156A (zh) 2015-01-07
EP2819697A1 (en) 2015-01-07
NZ629178A (en) 2016-09-30
US9732156B2 (en) 2017-08-15
CN104271156B (zh) 2017-06-16
KR20140130513A (ko) 2014-11-10
CO7061039A2 (es) 2014-09-19
MX2014010447A (es) 2015-06-23
CA2865501A1 (en) 2013-09-06
AU2013203619B2 (en) 2015-02-26
EP3255063A2 (en) 2017-12-13
US20130224210A1 (en) 2013-08-29
HK1204981A1 (en) 2015-12-11
MX2018007630A (es) 2023-04-12
ZA201406318B (en) 2016-07-27
JP6343368B2 (ja) 2018-06-13
AP2014007921A0 (en) 2014-09-30
EP3255063A3 (en) 2018-02-07
EA201491599A1 (ru) 2015-05-29
SG11201405273YA (en) 2014-09-26
CL2014002258A1 (es) 2015-02-20
JP6144286B2 (ja) 2017-06-07
MD20140108A2 (ro) 2015-03-31
SG10201610788VA (en) 2017-03-30
ECSP14020644A (es) 2015-09-30

Similar Documents

Publication Publication Date Title
BR112014021081A2 (pt) anticorpos para a metaloproteinase da matriz 9
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
BR112014021477A2 (pt) anticorpos para metaloproteinase de matriz 9
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
AR103488A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
CO7250445A2 (es) Proteínas de unión a antígeno st2
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
CO6630164A2 (es) Proteinas que se unen al tnf-a
BR112015006060A2 (pt) agentes de ligação kir3dl2
AR093984A1 (es) Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
BR112013021562A2 (pt) anticorpos para cd70
BR112016004324A2 (pt) anticorpos
BR112015029300A2 (pt) Anticorpo biespecífico, composição farmacêutica compreendendo o mesmo, seus usos, usos de um anticorpo anti-ccl2, e um anticorpo anti-loxl2, ou seus fragmentos e kit
BR112015017981A2 (pt) anticorpo humano específico para metapneumovírus humano, ou fragmento de ligação de antígeno do mesmo, seu uso e composição farmacêutica o compreendendo, bem como ácido nucleico isolado, vetor de expressão recombinante e célula hospedeira
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
AR118080A2 (es) Proteínas de unión a antígeno dirigidas contra el receptor
DOP2012000266A (es) PROTEÍNAS QUE SE UNEN AL TNF-a

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2619 DE 16-03-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.